Cargando…

Male Breast Cancer: From Molecular Genetics to Clinical Management

SIMPLE SUMMARY: Male breast cancer (MBC) is a rare disease. Genetic factors predispose to male breast cancer. Germline and/or genetic and/or epigenetic alterations at the somatic level identify a subset of male breast cancer that could differ from female breast cancer (FBC). Cancer genetic counselin...

Descripción completa

Detalles Bibliográficos
Autores principales: Pensabene, Matilde, Von Arx, Claudia, De Laurentiis, Michelino
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9030724/
https://www.ncbi.nlm.nih.gov/pubmed/35454911
http://dx.doi.org/10.3390/cancers14082006
_version_ 1784692211868237824
author Pensabene, Matilde
Von Arx, Claudia
De Laurentiis, Michelino
author_facet Pensabene, Matilde
Von Arx, Claudia
De Laurentiis, Michelino
author_sort Pensabene, Matilde
collection PubMed
description SIMPLE SUMMARY: Male breast cancer (MBC) is a rare disease. Genetic factors predispose to male breast cancer. Germline and/or genetic and/or epigenetic alterations at the somatic level identify a subset of male breast cancer that could differ from female breast cancer (FBC). Cancer genetic counseling should be included in the work-up of male breast cancer to identify the possible genetic origin of the tumor and to offer patients and their at-risk family members adequate management. ABSTRACT: MBC is a rare disease accounting for almost 1% of all cancers in men and less than 1% of breast cancer. Emerging data on the genetic drivers of predisposition for MBC are available and different risk factors have been associated with its pathogenesis. Genetic alterations, such as pathogenetic variants in BRCA1/2 and other moderate-/low-penetrance genes, along with non-genetic risk factors, have been recognized as pathogenic factors for MBC. Preventive and therapeutic implications could be related to the detection of alterations in predisposing genes, especially BRCA1/2, and to the identification of oncogenic drivers different from FBC. However, approved treatments for MBC remain the same as FBC. Cancer genetic counseling has to be considered in the diagnostic work-up of MBC with or without positive oncological family history. Here, we review the literature, reporting recent data about this malignancy with a specific focus on epidemiology, and genetic and non-genetic risk factors. We introduce the perspective of cancer genetic counseling for MBC patients and their healthy at-risk family members, with a focus on different hereditary cancer syndromes.
format Online
Article
Text
id pubmed-9030724
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-90307242022-04-23 Male Breast Cancer: From Molecular Genetics to Clinical Management Pensabene, Matilde Von Arx, Claudia De Laurentiis, Michelino Cancers (Basel) Review SIMPLE SUMMARY: Male breast cancer (MBC) is a rare disease. Genetic factors predispose to male breast cancer. Germline and/or genetic and/or epigenetic alterations at the somatic level identify a subset of male breast cancer that could differ from female breast cancer (FBC). Cancer genetic counseling should be included in the work-up of male breast cancer to identify the possible genetic origin of the tumor and to offer patients and their at-risk family members adequate management. ABSTRACT: MBC is a rare disease accounting for almost 1% of all cancers in men and less than 1% of breast cancer. Emerging data on the genetic drivers of predisposition for MBC are available and different risk factors have been associated with its pathogenesis. Genetic alterations, such as pathogenetic variants in BRCA1/2 and other moderate-/low-penetrance genes, along with non-genetic risk factors, have been recognized as pathogenic factors for MBC. Preventive and therapeutic implications could be related to the detection of alterations in predisposing genes, especially BRCA1/2, and to the identification of oncogenic drivers different from FBC. However, approved treatments for MBC remain the same as FBC. Cancer genetic counseling has to be considered in the diagnostic work-up of MBC with or without positive oncological family history. Here, we review the literature, reporting recent data about this malignancy with a specific focus on epidemiology, and genetic and non-genetic risk factors. We introduce the perspective of cancer genetic counseling for MBC patients and their healthy at-risk family members, with a focus on different hereditary cancer syndromes. MDPI 2022-04-15 /pmc/articles/PMC9030724/ /pubmed/35454911 http://dx.doi.org/10.3390/cancers14082006 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Pensabene, Matilde
Von Arx, Claudia
De Laurentiis, Michelino
Male Breast Cancer: From Molecular Genetics to Clinical Management
title Male Breast Cancer: From Molecular Genetics to Clinical Management
title_full Male Breast Cancer: From Molecular Genetics to Clinical Management
title_fullStr Male Breast Cancer: From Molecular Genetics to Clinical Management
title_full_unstemmed Male Breast Cancer: From Molecular Genetics to Clinical Management
title_short Male Breast Cancer: From Molecular Genetics to Clinical Management
title_sort male breast cancer: from molecular genetics to clinical management
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9030724/
https://www.ncbi.nlm.nih.gov/pubmed/35454911
http://dx.doi.org/10.3390/cancers14082006
work_keys_str_mv AT pensabenematilde malebreastcancerfrommoleculargeneticstoclinicalmanagement
AT vonarxclaudia malebreastcancerfrommoleculargeneticstoclinicalmanagement
AT delaurentiismichelino malebreastcancerfrommoleculargeneticstoclinicalmanagement